15 Sept 2026 · Global Head of Medical Affairs · 4 products in scope · FY2026
Strategic objective progress
Tier 1 stakeholder coverage
MI SLA compliance
Launch readiness (Vantrexa)
13 items: overdue tasks, decisions awaiting leadership, escalated risks and unread notifications
Latest audit events across the hub
Dr. Helen Okafor signed in to session u-helen
15 Sept 2026, 07:42 UTC · UI · AUD-001815
Grace Nakamura updated stakeholder STK-0007 · dataQuality Good → Duplicate suspected
15 Sept 2026, 02:00 UTC · Integration · AUD-001811
James Whitfield updated initiative INI-0068 · dueDate Draft → Submitted
14 Sept 2026, 18:43 UTC · UI · AUD-002099
James Whitfield updated publication PUB-0091 · summary Draft → Reviewed
14 Sept 2026, 18:12 UTC · Integration · AUD-002134
Mei Tanaka updated initiative INI-0117 · status — → Reviewed
14 Sept 2026, 14:09 UTC · UI · AUD-002033
Dr. Anna Becker created initiative INI-0071 · dueDate Draft → Completed
14 Sept 2026, 13:27 UTC · Integration · AUD-002102
Luis Ortega created engagement ENG-0023 · topics — → In progress
14 Sept 2026, 13:23 UTC · UI · AUD-002151
James Whitfield updated initiative INI-0099 · dueDate — → In progress
14 Sept 2026, 12:57 UTC · UI · AUD-002144
vantrelimab · Oncology
Objective progress
5 objectives · 7 initiatives (2 at risk or blocked) · lead Dr. Priya Raman
nephradin · Nephrology
Objective progress
3 objectives · 3 initiatives (1 at risk or blocked) · lead Dr. Marcus Lindqvist
lumevarin · Neurology
Objective progress
3 objectives · 3 initiatives (1 at risk or blocked) · lead Dr. Elena Moretti
aurelinate · Immunology
Objective progress
1 objectives · 1 initiatives (0 at risk or blocked) · lead Dr. Tomás Ferreira